XBIvsIBRNETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. iShares Neuroscience and Healthcare ETF (IBRN) is part of the Healthcare Technology segment. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, IBRN's top sector exposures are Healthcare and Non-Corporate. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.47% for IBRN. XBI is up 22.77% year-to-date (YTD) with +$853M in YTD flows. IBRN performs worse with -3.08% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of XBI and IBRN below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs IBRN performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/23/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI IBRN | -3.93%-8.14% | -1.72%-17.21% | +22.77%-3.08% | +39.61%+9.13% | +130.21%+61.85% | +20.98%n/a |
| Flows | XBI IBRN | +$229M- | +$343M+$2M | +$853M+$2M | +$1.24B+$2M | +$276M+$759K | +$1.96B- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI IBRN | +30.32%+25.93% | +29.02%+26.78% | +28.46%+25.48% | +33.06%n/a |
| Max drawdown | XBI IBRN | -14.89%-26.38% | -14.89%-26.38% | -32.94%-34.98% | -53.28%n/a |
| Max drawdown duration | XBI IBRN | 65d65d | 65d65d | 331d338d | 1622dn/a |
Trading data
XBI | IBRN | |
Last sale 10/26/2026 at 1:30 PM | $150.51 | $31.49 |
| Previous close 10/23/2026 | $149.54 | $31.36 |
| Consolidated volume 10/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | IBRN | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/26/2026 at 1:30 PM
Live
Closed
XBI | IBRN | |
|---|---|---|
| Last price | $150.51 | $31.49 |
| 1D performance | +0.65% | +0.40% |
| AuM | $10.36 B | $6.26 M |
| E/R | 0.35% | 0.47% |
Characteristics
XBI | IBRN | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | iShares |
| Benchmark | S&P Biotechnology Select Industry Index | NYSE FactSet Global Neuro Biopharma and MedTech Index |
| N° of holdings | 149 | 69 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | August 24, 2022 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.53%
Other
4.47%
IBRN
USA
73.41%
Other
26.59%
Sectors
XBI
Healthcare
99.18%
Other
0.82%
IBRN
Healthcare
99.86%
Other
0.14%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
21.91%
IBRN
Total weight of top 15 holdings out of 15
62.03%
Top 15 holdings
Data as of August 31, 2026
XBI
Moderna, Inc.
2.81%
Twist Bioscience Corp.
1.89%
Apogee Therapeutics, Inc.
1.50%
Kymera Therapeutics, Inc.
1.40%
Halozyme Therapeutics, Inc.
1.39%
Natera, Inc.
1.37%
Praxis Precision Medicines, Inc.
1.34%
Oruka Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.31%
Travere Therapeutics, Inc.
1.30%
Protagonist Therapeutics, Inc.
1.28%
Dianthus Therapeutics, Inc.
1.27%
CG Oncology, Inc.
1.26%
Vaxcyte, Inc.
1.23%
Erasca, Inc.
1.23%
IBRN
Praxis Precision Medicines, Inc.
5.21%
Dianthus Therapeutics, Inc.
4.96%
ACADIA Pharmaceuticals, Inc.
4.93%
Scholar Rock Holding Corp.
4.85%
Xenon Pharmaceuticals, Inc.
4.40%
argenx SE
4.37%
Arrowhead Pharmaceuticals, Inc.
4.26%
Biogen, Inc.
4.19%
Alkermes Plc
4.15%
PTC Therapeutics, Inc.
3.70%
Denali Therapeutics, Inc.
3.56%
Neurocrine Biosciences, Inc.
3.55%
Dyne Therapeutics, Inc.
3.38%
Edgewise Therapeutics, Inc.
3.30%
Axsome Therapeutics, Inc.
3.23%
Frequently asked questions about XBI and IBRN
How have the XBI and IBRN ETFs performed in 2026?
As of October 23, 2026, XBI is up 22.77% year-to-date (YTD), while IBRN has lost -3.08%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or IBRN?
Year-to-date, the XBI ETF saw +$853M in flows, compared to +$2M for IBRN.
Which ETF is more volatile: XBI or IBRN?
Over the past year, XBI had a volatility of 29.02%, while IBRN experienced 26.78%.
Which ETF is bigger: XBI or IBRN?
As of October 23, 2026, XBI holds $10.36 B in assets under management (AUM), while IBRN manages $6.26 M.
What sectors do the XBI and IBRN ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, IBRN focuses on Healthcare.
What are the top holdings of the XBI ETF and IBRN ETF?
XBI top holdings include Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc.. IBRN holds in its top three: Praxis Precision Medicines, Inc., Dianthus Therapeutics, Inc. and ACADIA Pharmaceuticals, Inc..
Which ETF is more diversified: XBI or IBRN?
XBI holds 152 securities with 21.91% of its assets in the top 15. IBRN has 69 securities and a top 15 weight of 62.03%.
Advertisement
Latest news about XBI & IBRN
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
